JMERC
Owner
Janbazan Medical and Engineering Research Center (JMERC) is the owner of IJWPH.
0.4
Cite Score
SJR: 0.114 / SNIP: 0.090
Volume 16, Issue 2 (2024)
Iran J War Public Health 2024, 16(2): 1001-1020 |
Back to browse issues page
Article Type:
Subject:
History
Received: 2024/08/28 | Accepted: 2024/08/28 | Published: 2024/06/21
Received: 2024/08/28 | Accepted: 2024/08/28 | Published: 2024/06/21
How to cite this article
Al-Oudah G, Ali S A, Mohammed S, Al-Ameedee H, Al-Ameedee A, Sahib A et al . Clinical and Anti-Oxidant Effect of Adding Coq10 To Biological Therapy In Treating Moderate To Severe Psoriasis. Iran J War Public Health 2024; 16 (2) :1001-1020
URL: http://ijwph.ir/article-1-1504-en.html
URL: http://ijwph.ir/article-1-1504-en.html
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Rights and permissions
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Authors
G.A. Al-Oudah *1, Sana Abdul-Jabbar Ali2, S.M. Mohammed3, H.A. Al-Ameedee4, A.A. Al-Ameedee4, A.S. Sahib5, M.K. Al-Hattab6
1- Pharmacy College, Al-Mustaqbal University, Babil, Iraq , ghada.ali@uomus.edu.iq
2- Al-Safwa University College, Karbala Iraq
3- Pharmacy College, Al-Mustaqbal University, Babil, Iraq
4- MBChB Resident Doctor at Babil Health Directorate, Iraqi Ministry of Health, Iraq
5- Department of Pharmacology, College of Pharmacy, University of Karbala, Karbala, Iraq
6- Department of Dermatology, Hammurabi Medical College, University of Babylon, Iraq
2- Al-Safwa University College, Karbala Iraq
3- Pharmacy College, Al-Mustaqbal University, Babil, Iraq
4- MBChB Resident Doctor at Babil Health Directorate, Iraqi Ministry of Health, Iraq
5- Department of Pharmacology, College of Pharmacy, University of Karbala, Karbala, Iraq
6- Department of Dermatology, Hammurabi Medical College, University of Babylon, Iraq
Abstract (122 Views)
Aims: Psoriasis is an inflammatory skin disease that is complex, chronic, immune-mediated, and has a hereditary basis. Oxidative imbalance is documented in psoriasis, and exposure to ROS is responsible for keratinocyte destruction, leading to pro-inflammatory mediators to be released
and recruitment of immune cells, thus, it is possible that CoQ10 therapy may modify the function of oxidative stress, subsequently inhibiting keratinocyte proliferation. The goal of the present study attempts the addition of CoQ10 to biological therapy can help to relieve inflammation from Iraqi patients suffering from moderate to severe psoriasis Subjects and Methods: The investigational group involves thirty individuals with moderate to severe psoriasis were divided into (2) groups at random: Fifteen psoriatic patients received treatment with 40 mg of Adalimumab twice a month for a period of twelve weeks in Group A. Similarly, fifteen psoriatic patients received treatment with 40 mg of Adalimumab twice a month in Group B, along with a daily dose of 100 mg of CoQ10. The percentage improvement changes during the treatment period were assessed using the psoriasis area and severity index (PASI). In addition, serum levels for oxidative stress indicators, including SOD and MDA, were measured before and after therapy using the ELISA technique .Results: When compared to the patients before treatment, the two groups showed a substantial decline (p<0.05) after treatment; however, group B, which added CoQ10 to biological treatment, showed a highly significant decrease (p<0.05) in mean SOD level and MDA after treatment. Furthermore, following twelve weeks of treatment, group B's use of combined adjuvant therapy showed even greater recovery, as indicated by a 79% PIC PASI score improvement as opposed to a 60% PIC score. Conclusion: This trail exhibits that addition everyday dose of CoQ10 to biological treatment has additional positive impact on reducing oxidative stress related to psoriasis.
and recruitment of immune cells, thus, it is possible that CoQ10 therapy may modify the function of oxidative stress, subsequently inhibiting keratinocyte proliferation. The goal of the present study attempts the addition of CoQ10 to biological therapy can help to relieve inflammation from Iraqi patients suffering from moderate to severe psoriasis Subjects and Methods: The investigational group involves thirty individuals with moderate to severe psoriasis were divided into (2) groups at random: Fifteen psoriatic patients received treatment with 40 mg of Adalimumab twice a month for a period of twelve weeks in Group A. Similarly, fifteen psoriatic patients received treatment with 40 mg of Adalimumab twice a month in Group B, along with a daily dose of 100 mg of CoQ10. The percentage improvement changes during the treatment period were assessed using the psoriasis area and severity index (PASI). In addition, serum levels for oxidative stress indicators, including SOD and MDA, were measured before and after therapy using the ELISA technique .Results: When compared to the patients before treatment, the two groups showed a substantial decline (p<0.05) after treatment; however, group B, which added CoQ10 to biological treatment, showed a highly significant decrease (p<0.05) in mean SOD level and MDA after treatment. Furthermore, following twelve weeks of treatment, group B's use of combined adjuvant therapy showed even greater recovery, as indicated by a 79% PIC PASI score improvement as opposed to a 60% PIC score. Conclusion: This trail exhibits that addition everyday dose of CoQ10 to biological treatment has additional positive impact on reducing oxidative stress related to psoriasis.
Keywords:
Send email to the article author